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Abstract: Cardiovascular disease is the leading cause of death worldwide, with high 
medical costs and rates of disability. It is therefore important to evaluate the use of 
cardiovascular biomarkers in the early diagnosis of coronary artery disease (CAD). We 
have screened a variety of recently identified bioactive peptides candidates in anticipation 
that they would allow detection of atherosclerotic CAD. Especially, we have focused on 
novel anti-atherogenic peptides as indicators and negative risk factors for CAD. In vitro,  
in vivo and clinical studies indicated that human adiponectin, heregulin-β1, glucagon-like  
peptide-1 (GLP-1), and salusin-α, peptides of 244, 71, 30, and 28 amino acids, respectively, 
attenuate the development and progression of atherosclerotic lesions by suppressing 
macrophage foam cell formation via down-regulation of acyl-coenzyme A: cholesterol 
acyltransferase-1. Circulating levels of these peptides in the blood are significantly 
decreased in patients with CAD compared to patients without CAD. Receiver operating 
characteristic analyses showed that salusin-α is a more useful biomarker, with better 
sensitivity and specificity, compared with the others for detecting CAD. Therefore,   
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salusin-α, heregulin-β1, adiponectin, and/or GLP-1, alone or in various combinations, may 
be useful as biomarkers for atherosclerotic CAD. 
Keywords: acyl-coenzyme A: cholesterol acyltransferase-1; adiponectin; atherosclerosis; 
biomarker; coronary artery disease; glucagon-like peptide-1; heregulin-β1; macrophage, 
salusin-α 
 
1. Introduction 
Over the past two decades, biomarkers have become increasingly utilized to improve overall patient 
care [1]. For example, biomarkers have had a significant impact in early detection of sub-clinical 
disease, diagnosis of acute or chronic syndromes, risk stratification, and in monitoring of disease and 
therapeutic efficacy [1]. Biomarkers are generally considered to be proteins or enzymes—measured in 
serum, plasma, or blood—that provide independent diagnostic and/or prognostic value by reflecting an 
underlying disease state [2].  
Potential biomarkers have been extensively evaluated in the field of cardiovascular medicine   
as well as oncology [1]. Classical risk factors, such as lipids and glucose, have been well-established in 
coronary artery disease (CAD), while four additional markers have sufficient evidence of clinical 
utility to be recommended for regular clinical use: (1) cardiac troponin I and T; (2) B-type natriuretic 
peptides; (3) D-dimer; and (4) C-reactive protein (CRP) [1]. For example, epidemiological data 
demonstrated an association between high-sensitivity CRP and risk of future cardiovascular morbidity 
and mortality among those at high risk or with documented CAD [3]. 
However, only a limited number of markers have demonstrated significant diagnostic and/or 
therapeutic impact. Deeper insights into the pathophysiology of atherosclerosis have led to the 
discovery of additional novel biomarkers [1]. New vasoactive agents, inflammatory cytokines, and 
oxidative products that have attracted attentions have been implicated as potential biomarkers [1,2,4,5]. 
Previous studies have shown that high levels of pro-atherogenic vasoactive agents, such as serotonin 
and urotensin II, can be used as biomarkers for CAD [6,7]. Moreover, reduced circulating levels of 
anti-atherogenic vasoactive agents could also be used as indicators and/or negative risk factors for 
CAD [8,9]. In subsequent trials, we have focused on novel anti-atherogenic peptides; adiponectin,  
an adipocytokine [10], heregulin-β1 (neuregulin-1 type I), a neuron growth factor [9], glucagon-like 
peptide-1 (GLP-1), an incretin hormone [11], and salusin-α, a peptide recently identified by an in silico 
approach [8]. 
Atherosclerosis is a pathological injury-to-response process that is initiated by early inflammatory 
responses of vascular endothelial cells [12]. Endothelial inflammation is characterized by decreased 
nitric oxide production, and monocyte adhesion and infiltration into the neointima lesion, followed by 
oxidized low-density lipoprotein (LDL)-induced transformation of macrophages into foam cells [12]. 
Vascular smooth muscle cell (VSMC) and fibroblast proliferation also plays an important role in the 
development of atherosclerotic lesions [12]. Therefore, any potent bioactive factors modulating such 
pathogenetic process could possibly be clinical atherosclerotic biomarkers. Sensors 2012, 12  4976 
 
 
This review focuses on the protective roles of adiponectin, heregulin-β1, GLP-1, and salusin-α in 
atherosclerotic cardiovascular diseases and their emerging roles for biomarkers and therapeutic targets 
for CAD. 
2. Roles in the Cardiovascular System 
Human adiponectin, heregulin-β1, GLP-1, and salusin-α are peptides of 244, 71, 30, and   
28 amino acids, respectively. Adiponectin and GLP-1 are produced predominantly by adipose tissue 
and the L-cells of the lower gut, respectively, and less by the cardiovascular disease [10,13]. Salusin-α  
and heregulin-β1 are both expressed in monocytes/macrophages, vascular endothelial cells, and   
VSMCs [9,14]. Receptors of adiponectin (AdipoR1 and AdipoR2), heregulin-β1 (ErbB3 and ErbB4), 
and GLP-1 (GLP-1R) are abundantly expressed in human monocytes and macrophages [11,15,16], 
endothelial cells [10,17,18], VSMCs [11,19,20], and cardiomyocytes [21−23], while salusin-α receptors 
have not yet been identified [8,14].  
As indicated in Table 1, adiponectin, heregulin-β1, and GLP-1 suppress VSMC proliferation [11,20,24], 
show anti-inflammatory and anti-oxidant effects [18,25−29], and promote endothelial nitric oxide 
production [30−32]. Adiponectin, heregulin-β1, and GLP-1 have been shown to exhibit cardioprotective 
effects against ischemic injury [33−35]. GLP-1 stimulates insulin secretin from pancreatic islet β-cells 
and lowers blood pressure [13]. GLP-1 and adiponectin are also known to ameliorate insulin 
resistance, lipid metabolism, and obesity [13,36]. Salusin-α has been shown to lower blood pressure, to 
promote mildly VSMC and fibroblast proliferation, and to suppress cardiomyocyte apoptosis, but no 
effect on endothelial nitric oxide production [14,37]. Other vasoactive effects of salusin-α have not yet 
been clarified [8]. 
Table 1. Effects of new novel peptides on the cardiovascular system. 
 Adiponectin  Heregulin-β1 GLP-1  Salusin-α 
VSMC proliferation  ↓  ↓  ↓  ↑ 
eNOS  ↑  ↑  ↑  → 
Cardiomyocyte  protection  +  + + + 
Anti-inflammation +  +  +  NE 
Anti-oxidation +  + +  NE 
GLP-1: glucagon-like peptide-1, VSMC: vascular smooth muscle cell, eNOS: endothelial nitric 
oxide synthase, NE: not examined. Arrows indicate either stimulation or suppression of VSMC 
proliferation and eNOS induction. + indicates positive effects.  
3. Anti-Atherosclerotic Effects  
Interestingly, adiponectin, heregulin-β1, GLP-1, and salusin-α show common suppressive effects on 
macrophage-driven atherosclerosis. As listed in Table 2, adiponectin, heregulin-β1, and salusin-α 
suppress foam cell formation, as indicated by cholesterol ester accumulation induced by acetylated 
LDL in primary cultured human monocyte-derived macrophages [16,38,39]. The intracellular free 
cholesterol level is increased by the endocytic uptake of acetylated LDL via scavenger receptor class A 
(SR-A) and is decreased by efflux of free cholesterol mediated by ATP-binding cassette transporter A1 
(ABCA1) [12]. As excessive accumulation of free cholesterol is toxic to cells, free cholesterol must be Sensors 2012, 12  4977 
 
 
either removed through efflux to extracellular acceptors, such as apolipoprotein (apo) A1 and   
high-density lipoprotein, or esterified to cholesterol ester by the microsomal enzyme acyl-coenzyme A: 
cholesterol acyltransferase-1 (ACAT1) [12]. As indicated in Table 2, adiponectin, heregulin-β1, and 
salusin-αsuppress ACAT1 expression in human monocyte-derived macrophages [16,38,39]. GLP-1 has 
been shown to suppress foam cell formation and ACAT1 expression in mouse macrophages [11]. 
Adiponectin and heregulin-β1, but not salusin-α, suppress SR-A expression and enhance ABCA1 
expression in human monocyte-derived macrophages [16,39−41] (Table 2). Adiponectin up-regulates 
ABCA1 via peroxisome proliferator-activated receptor-γ ( PPARγ) and liver X receptor (LXR) 
signaling pathways in human macrophages [42]. 
Table 2. Effects of new novel peptides on macrophage foam cell formation. 
 Adiponectin  Heregulin-β1 GLP-1  Salusin-α 
Foam cell formation  ↓  ↓  ↓  ↓ 
ACAT1  ↓  ↓  ↓  ↓ 
SR-A  ↓  ↓  →  → 
ABCA1  ↑  ↑  →  → 
GLP-1: glucagon-like peptide-1, ACAT1: acyl-coenzyme A:  cholesterol acyltransferase-1,   
SR-A: scavenger receptor class A, ABCA1: ATP-binding cassette transporter A1. Arrows indicate 
stimulatory, suppressive, or negative effects. 
Further, we and other groups have documented the anti-atherosclerotic effects of adiponectin, 
heregulin-β1, GLP-1, and salusin-α by treatments of each peptide into apoE-knockout mice as an 
established animal model of atherosclerosis [11,16,43,44]. Treatments with adiponectin, heregulin-β1, 
GLP-1, or salusin-α significantly attenuated aortic atherosclerotic lesions accompanied with   
a significant decrease in macrophage infiltration [11,16,43,44]. Significant suppressions of oxidized 
LDL-induced foam cell formation and ACAT1 expression were documented ex vivo in exudate 
peritoneal macrophages from apoE-knockout mice infused with GLP-1 or salusin-α compared with 
those from vehicle-infused apoE-knockout mice [11,44]. In these experiments, GLP-1 also 
downregulated CD36 that contributes to the endocytic uptake of oxidized LDL into macrophages [11]. 
Macrophage foam cells were less observed in aortic atherosclerotic lesions from adiponectin-transgenic 
LDL receptor-knockout mice fed with high-fat diet [45].  
4. Presence in Coronary Artery Atherosclerosis and Circulating Blood 
Immunohistochemical analyses of human coronary arteries from patients with CAD using   
anti-heregulin-β1 or anti-salusin-α antibodies show faint staining in advanced coronary atherosclerotic 
lesions, suggesting decreased expression at their protein levels [16,39]. The expression of adiponectin 
at mRNA levels is also significantly lower in epicardial adipose tissues in CAD [46]. These findings 
strongly suggest that a decline in anti-atherogenic peptides may be associated with the progression of 
atherosclerotic lesions in human coronary arteries.  
Circulating markers are more convenient for diagnosis of CAD. As specific antibodies against these 
peptides have been developed, their concentrations in blood samples could be quantified using 
radioimmunoassay and enzyme-linked immunosorbent assay (ELISA). Serum levels of total and   Sensors 2012, 12  4978 
 
 
high-molecular weight adiponectin and plasma heregulin-β1 levels were measured by ELISA, and their 
accuracy and precision were comparable among several studies [16,47−53]. The accuracy and 
precision of serum salusin-α and plasma GLP-1 levels measured by radioimmunoassay and ELISA 
were identical among each several studies [39,54−59]. 
To assess essential levels of peptide hormones, the factors that influence peptide production must be 
taken into consideration. In general, these include food intake, smoking, gender, and the presence  
of diabetes, hypertension or obesity. Serum salusin-α and plasma heregulin-β1 levels have been 
demonstrated to be unaffected by a number of physiological stimuli [8,9]. Since adiponectin is known 
to show sexual dimorphism with higher levels in women than men, von Eynatten et al. [48] have 
studied serum adiponectin levels in the limited male subjects. Because GLP-1 is temporary increased 
after food intake, plasma GLP-1 levels have been measured in the fasting state and/or after 75-g oral 
glucose tolerance test [60−62]. Similar to adiponectin measurements, we determined serum salusin-α 
and plasma heregulin-β1 levels in the fasting state [16,39]. 
5. Biomarkers for CAD  
Matsubara et al. [60] reported that fasting plasma GLP-1 levels are significantly lower in CAD 
patients than in non-CAD patients (3.1 [2.4−3.6] versus 4.0 [3.1−5.9] pM, P < 0.001). Among patients 
without diabetes, the fasting plasma GLP-1 levels in CAD patients are significantly lower than in  
non-CAD patients (3.2 [2.6−3.7] versus 3.9 [3.0−5.2] pM, P < 0.001) [60]. However, Nathanson et al. [62] 
reported that impaired GLP-1 secretion after oral glucose load does not predict CAD in the presence of 
diabetes. El-Menyar et al. [63] reported that serum levels of high-molecular weight adiponectin are 
significantly decreased in CAD patients compared with those in non-CAD patients (1.9 ± 0.2 versus 
3.1 ± 0.3 μg/mL, P = 0.003). Serum levels of high-molecular weight adiponectin were shown to be 
inversely correlated with angiographic severity of coronary artery lesions in patients with CAD [48]. 
Circulating levels of heregulin-β or salusin-α are also significantly decreased (Figure 1) and inversely 
correlated with angiographic severity of coronary artery lesions in patients with CAD [16,39,53]. 
Receiver operating characteristic (ROC) curves were plotted and the area under the curve (AUC) 
was analyzed to compare the predictive power of high-molecular weight adiponectin, heregulin-β1, and 
salusin-α. The optimal cut-off values of these peptides for detecting CAD were set at the point 
showing a higher true-positive rate (sensitivity) with a low false-positive rate (1-specifity) on the 
respective ROC curve. von Eynatten et al. [48] reported that the AUC value for high-molecular weight 
adiponectin was 0.673. The ROC curve was slightly improved by using the high-molecular weight 
adiponectin/total adiponectin ratio, and its AUC value became 0.718. On the basis of our previous 
studies [16,39], we also performed ROC analyses and calculated the AUC values in the present time. 
The AUC values of heregulin-β1 and salusin-α are 0.706 and 0.916, respectively (Figure 2).   
In addition, the cut-off levels were 2.4 ng/mL for heregulin-β1 with sensitivity and specificity of 76.6% 
and 58.1%, respectively, and that for salusin-α was 8.5 pM with sensitivity and specificity of 81.5% 
and 92.7%, respectively. In comparisons among these peptides, the AUC values for high-molecular 
weight adiponectin and the high-molecular weight adiponectin/total adiponectin ratio were similar to 
that of heregulin-β1 but inferior to that of salusin-α Therefore, serum salusin-α level has higher 
diagnostic value in detecting CAD compared with the other three peptides. S
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dysfunction [52,66]. Thus, further studies are required to determine their utility as biomarkers in 
predicting atherosclerotic CAD in the presence or absence of severe heart failure. 
Recently, several studies have shown that administration of heregulin-β1 or GLP-1 improves cardiac 
dysfunction in patients with heart failure [67−71]. Intracoronary administration of adiponectin   
led to a reduction in myocardial infarct size and improvement of left ventricular function after 
ischemia/reperfusion injury in pigs [72]. However, effects of adiponectin and salusin-α on cardiac 
function have not yet been reported in humans. These findings provide insights into the potential use of 
heregulin-β1 or GLP-1 as an extended therapeutic window for combating refractory heart failure.  
7. Conclusions 
Adiponectin, heregulin-β1, GLP-1, and salusin-α could contribute to the early diagnosis and 
therapeutic efficacy of atherosclerosis. Decreased levels of adiponectin, heregulin-β1, GLP-1 and 
salusin-α in circulating blood and/or cardiovascular tissues are closely linked with human 
atherosclerosis. Thus, adiponectin, heregulin-β1, GLP-1, and/or salusin-α, alone or in various 
combinations are candidate biomarkers for predicting CAD, which may be useful for the earlier 
detection of atherosclerotic cardiovascular diseases. 
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